ExL Pharma's European Digital Marketing and Public Relations Conferences

Bayer Schering Pharma and ExL Pharma announced that the 2nd Annual Digital Pharma Europe and 2nd Annual European Public Relations and Communications Summit will be hosted at the Bayer Schering Pharma World Headquarters in Berlin, Germany on March 29-30, 2010.

These events which feature 50+ executive-level speakers from top industry leaders provide comprehensive presentations, panel discussions and opportunities for dialogue on issues that are most relevant to social media, web 2.0 technologies, product communications and corporate communications. 300+ executives are expected to attend from leading pharmaceutical, biotechnology and medical device organizations worldwide.

Bryon Main, Managing Director of ExL Pharma, states, "Coming off the heels of ExL's successful European pharmaceutical conferences this year, we are very pleased to be partnering with Bayer Schering Pharma for our 2nd Public Relations and 2nd Digital Pharma Summits. This marks the first time that major industry education conferences will be hosted by a leading pharmaceutical organization in Europe."

These events will provide concrete strategies for a range of timely topics relevant to digital marketing and PR professionals, including how to build an organizational plan around social media and to prepare for and anticipate change within internal and external communications.

Past attendees of this conference had the following to say about their experience at these events:

"This conference was excellent. Top notch speakers and terrific networking opportunities with industry colleagues." - Susan Watkins, PR Director, Sanofi Pasteur.

"This conference was very comprehensive. We will definitely attend again next year." - Tricia Moriarty, Director of Commercial Communications, SEPRACOR

For further information, please visit:
http://www.exlpharma.com

About ExL Pharma
ExL Pharma, a division of ExL Events, Inc., is an international leader in developing innovative, educational events that serve the healthcare community and allied professionals. Behind our diverse conference portfolio, our experienced team conducts extensive market research and targeted outreach. The results translate into innovative, high-quality conference events designed to exceed the dynamic informational needs of the healthcare community.

About Bayer Schering
Bayer Schering Pharma is one of the ten largest specialty pharmaceutical companies in the world. It markets products in more than 100 countries worldwide and in 2008 generated sales of over EUR 10.7 billion.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...